282 related articles for article (PubMed ID: 11877262)
1. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Talpaz M; Silver RT; Druker BJ; Goldman JM; Gambacorti-Passerini C; Guilhot F; Schiffer CA; Fischer T; Deininger MW; Lennard AL; Hochhaus A; Ottmann OG; Gratwohl A; Baccarani M; Stone R; Tura S; Mahon FX; Fernandes-Reese S; Gathmann I; Capdeville R; Kantarjian HM; Sawyers CL
Blood; 2002 Mar; 99(6):1928-37. PubMed ID: 11877262
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Jabbour E; Kantarjian HM; Jones D; Shan J; O'Brien S; Reddy N; Wierda WG; Faderl S; Garcia-Manero G; Verstovsek S; Rios MB; Cortes J
Blood; 2009 Mar; 113(10):2154-60. PubMed ID: 19060245
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
Wetzler M; Donohue KA; Odenike OM; Feldman EJ; Hurd DD; Stone RM; Westerfelt P; Bloomfield CD; Larson RA
Leuk Lymphoma; 2008 Jul; 49(7):1274-8. PubMed ID: 18452072
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Santos FP; Kantarjian H; McConkey D; O'Brien S; Faderl S; Borthakur G; Ferrajoli A; Wright J; Cortes J
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):355-60. PubMed ID: 21816374
[TBL] [Abstract][Full Text] [Related]
5. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.
Jabbour EJ; Hughes TP; Cortés JE; Kantarjian HM; Hochhaus A
Leuk Lymphoma; 2014 Jul; 55(7):1451-62. PubMed ID: 24050507
[TBL] [Abstract][Full Text] [Related]
6. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cortes JE; Kantarjian HM; Rea D; Wetzler M; Lipton JH; Akard L; Khoury HJ; Michallet M; Guerci-Bresler A; Chuah C; Hellmann A; Digumarti R; Parikh PM; Legros L; Warzocha K; Baccarani M; Li E; Munteanu M; Nicolini FE
Cancer; 2015 May; 121(10):1637-44. PubMed ID: 25586015
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy Outcomes in Chronic Myeloid Leukemia: A Single Center Experience.
Madabhavi I; Sarkar M; Modi M; Kadakol N
J Glob Oncol; 2019 Sep; 5():1-11. PubMed ID: 31584851
[TBL] [Abstract][Full Text] [Related]
8. Morphologic Changes in the Bone Marrow in Patients of Chronic Myeloid Leukemia (CML) Treated with ImatinibMesylate.
Srinivas BH; Paul TR; Uppin SG; Uppin MS; Jacob RT; Raghunadharao D
Indian J Hematol Blood Transfus; 2012 Sep; 28(3):162-9. PubMed ID: 23997453
[TBL] [Abstract][Full Text] [Related]
9. Bilateral acute vision loss as the initial presentation of chronic myeloid leukemia in a young female.
Balamurugan S; Kaur K; Gurnani B; Agrawal A
Indian J Cancer; 2023 Oct; 60(4):578-582. PubMed ID: 38206079
[TBL] [Abstract][Full Text] [Related]
10. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
11. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
O'Brien SG; Guilhot F; Larson RA; Gathmann I; Baccarani M; Cervantes F; Cornelissen JJ; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Rousselot P; Reiffers J; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Kantarjian H; Taylor K; Verhoef G; Bolton AE; Capdeville R; Druker BJ;
N Engl J Med; 2003 Mar; 348(11):994-1004. PubMed ID: 12637609
[TBL] [Abstract][Full Text] [Related]
12. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Druker BJ; Tamura S; Buchdunger E; Ohno S; Segal GM; Fanning S; Zimmermann J; Lydon NB
Nat Med; 1996 May; 2(5):561-6. PubMed ID: 8616716
[TBL] [Abstract][Full Text] [Related]
13. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Ottmann OG; Druker BJ; Sawyers CL; Goldman JM; Reiffers J; Silver RT; Tura S; Fischer T; Deininger MW; Schiffer CA; Baccarani M; Gratwohl A; Hochhaus A; Hoelzer D; Fernandes-Reese S; Gathmann I; Capdeville R; O'Brien SG
Blood; 2002 Sep; 100(6):1965-71. PubMed ID: 12200353
[TBL] [Abstract][Full Text] [Related]
16. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Daley GQ; Van Etten RA; Baltimore D
Science; 1990 Feb; 247(4944):824-30. PubMed ID: 2406902
[TBL] [Abstract][Full Text] [Related]
17. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Johnson JR; Bross P; Cohen M; Rothmann M; Chen G; Zajicek A; Gobburu J; Rahman A; Staten A; Pazdur R
Clin Cancer Res; 2003 Jun; 9(6):1972-9. PubMed ID: 12796358
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Lugo TG; Pendergast AM; Muller AJ; Witte ON
Science; 1990 Mar; 247(4946):1079-82. PubMed ID: 2408149
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Saglio G; Hochhaus A; Goh YT; Masszi T; Pasquini R; Maloisel F; Erben P; Cortes J; Paquette R; Bradley-Garelik MB; Zhu C; Dombret H
Cancer; 2010 Aug; 116(16):3852-61. PubMed ID: 20564086
[TBL] [Abstract][Full Text] [Related]
20. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
Rowley JD
Nature; 1973 Jun; 243(5405):290-3. PubMed ID: 4126434
[No Abstract] [Full Text] [Related]
[Next] [New Search]
